NCT07521982Not yet recruiting
Comparison of Frailty, Physical Fitness Parameters, and Irisin Levels Between Patients With Multiple Sclerosis and Healthy Volunteers
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
Multiple Sclerosis (MS) is a chronic immune-mediated and neurodegenerative disease of the central nervous system that often affects young adults and is more common in women. In addition to neurological disability, individuals with MS frequently experience frailty, a condition characterized by reduced physiological reserve, weakness, fatigue, decreased physical activity, and increased vulnerability to stressors. Frailty in MS is associated with poorer mobility, higher fall risk, reduced quality of life, and increased healthcare utilization. Irisin, a hormone released from skeletal muscles during exercise, is linked to energy metabolism and muscle function, and lower levels have been associated with reduced physical performance and sarcopenia. However, the relationship between frailty, physical fitness, and irisin levels in individuals with MS has not been sufficiently explored. This study aims to compare frailty status, physical fitness parameters, and circulating irisin levels between patients with MS and healthy volunteers aged 18-65 years. Participants will undergo assessments including the Functional Independence Measure, Frailty Index, Berg Balance Scale, 6-Minute Walk Test, and handgrip strength measurement. Blood samples will also be collected to determine irisin levels using the ELISA method. Statistical analyses will evaluate differences between groups and correlations among frailty, functional performance, and irisin levels. The findings are expected to improve understanding of frailty mechanisms in MS and contribute to developing targeted rehabilitation and management strategies.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 782 (estimated)
- First submitted
- 12 Mar 2026
- Start date
- Apr 2026
- Primary completion date
- May 2026
- Lead sponsor
- Baskent University
- Diseases
- Multiple sclerosis
- NCT number
- NCT07521982
What you commit to
- Study type: Observational
- Planned participants: 782
- From Apr 2026 to the primary completion date, May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of any concomitant neurological disease other than MS.
- Having had an MS attack or received steroid treatment in the last month.
Other illness
- Presence of an uncontrolled systemic disease at a level that would affect the evaluation.
- Presence of cognitive impairment or psychiatric illness at a level that would affect the evaluation.
Age
- Being younger than 18 or older than 65.
Other
- Presence of an orthopedic disability that prevents evaluations.
Who the study is looking for
- Patients aged 18-65 evaluated by neurology and diagnosed with definitive MS via objective methods (MRI, lumbar puncture, etc.).
- Healthy volunteers aged 18-65.
- Being literate in Turkish.
- Participants who provide a consent form to participate in the study.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baskent University Alanya Hospital Coordinator of this site? Confirm its status | Antalya | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.